179 related articles for article (PubMed ID: 35046798)
1. Application of Population Pharmacokinetic Analysis to Characterize CYP2C19 Mediated Metabolic Mechanism of Voriconazole and Support Dose Optimization.
Li S; Wu S; Gong W; Cao P; Chen X; Liu W; Xiang L; Wang Y; Huang J
Front Pharmacol; 2021; 12():730826. PubMed ID: 35046798
[No Abstract] [Full Text] [Related]
2. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
[TBL] [Abstract][Full Text] [Related]
3. Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing.
Dolton MJ; Mikus G; Weiss J; Ray JE; McLachlan AJ
J Antimicrob Chemother; 2014 Jun; 69(6):1633-41. PubMed ID: 24554646
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics of Voriconazole in Chinese Patients with Hematopoietic Stem Cell Transplantation.
Chen C; Yang T; Li X; Ma L; Liu Y; Zhou Y; Ren H; Cui Y
Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):659-668. PubMed ID: 31041728
[TBL] [Abstract][Full Text] [Related]
5. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
[TBL] [Abstract][Full Text] [Related]
6. A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis.
Kim Y; Rhee SJ; Park WB; Yu KS; Jang IJ; Lee S
J Clin Med; 2019 Feb; 8(2):. PubMed ID: 30744151
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of Voriconazole and Dose Optimization in Elderly Chinese Patients.
Wang J; Shen Y; Wu Z; Ge W
J Clin Pharmacol; 2024 Feb; 64(2):253-263. PubMed ID: 37766506
[TBL] [Abstract][Full Text] [Related]
8. Model-based Voriconazole Dose Optimization in Chinese Adult Patients With Hematologic Malignancies.
Liu Y; Qiu T; Liu Y; Wang J; Hu K; Bao F; Zhang C
Clin Ther; 2019 Jun; 41(6):1151-1163. PubMed ID: 31079860
[TBL] [Abstract][Full Text] [Related]
9. CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.
Takahashi T; Mohamud MA; Smith AR; Jacobson PA; Jaber MM; Alharbi AF; Fisher J; Kirstein MN
Antimicrob Agents Chemother; 2021 Aug; 65(9):e0062321. PubMed ID: 34097481
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients.
Hu L; Huang S; Huang Q; Huang J; Feng Z; He G
PLoS One; 2023; 18(9):e0288794. PubMed ID: 37695751
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of Voriconazole in Patients With Invasive Aspergillosis: Serum Albumin Level as a Novel Marker for Clearance and Dosage Optimization.
Chantharit P; Tantasawat M; Kasai H; Tanigawara Y
Ther Drug Monit; 2020 Dec; 42(6):872-879. PubMed ID: 32947557
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetics of Voriconazole and Optimization of Dosage Regimens Based on Monte Carlo Simulation in Patients With Liver Cirrhosis.
Ren QX; Li XG; Mu JS; Bi JF; Du CH; Wang YH; Zhu H; Lv P; Zhao QG
J Pharm Sci; 2019 Dec; 108(12):3923-3931. PubMed ID: 31562869
[TBL] [Abstract][Full Text] [Related]
13. Application of a Physiologically Based Pharmacokinetic Model to Characterize Time-dependent Metabolism of Voriconazole in Children and Support Dose Optimization.
Zhang Y; Zhao S; Wang C; Zhou P; Zhai S
Front Pharmacol; 2021; 12():636097. PubMed ID: 33815119
[No Abstract] [Full Text] [Related]
14. Population pharmacokinetics of voriconazole and initial dosage optimization in patients with talaromycosis.
Jiang Z; Wei Y; Huang W; Li B; Zhou S; Liao L; Li T; Liang T; Yu X; Li X; Zhou C; Cao C; Liu T
Front Pharmacol; 2022; 13():982981. PubMed ID: 36225581
[TBL] [Abstract][Full Text] [Related]
15. Dosage optimization of voriconazole in children with haematological malignancies based on population pharmacokinetics.
Wu Y; Lv C; Wu D; Qi J; Cai R; Zhou S; Li C; Wei Y; Liu T
J Clin Pharm Ther; 2022 Dec; 47(12):2245-2254. PubMed ID: 36345158
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study.
Tang D; Yan M; Song BL; Zhao YC; Xiao YW; Wang F; Liang W; Zhang BK; Chen XJ; Zou JJ; Tian Y; Wang WL; Jiang YF; Gong GZ; Zhang M; Xiang DX
Br J Clin Pharmacol; 2021 Apr; 87(4):1890-1902. PubMed ID: 33010043
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects.
Muto C; Shoji S; Tomono Y; Liu P
Antimicrob Agents Chemother; 2015; 59(6):3216-23. PubMed ID: 25801557
[TBL] [Abstract][Full Text] [Related]
18. Combined Effect of
Chen J; Wu Y; He Y; Feng X; Ren Y; Liu S
Front Pediatr; 2022; 10():846411. PubMed ID: 35386257
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and covariate-based dosing individualization of voriconazole in lung transplant recipients.
Dvorackova E; Sima M; Vyskocilova K; Kotowski T; Dunovská K; Klapkova E; Havlin J; Lischke R; Slanar O
J Chemother; 2024 Feb; 36(1):35-44. PubMed ID: 37272077
[TBL] [Abstract][Full Text] [Related]
20. Impact of flavin-containing monooxygenase 3 and CYP2C19 genotypes on plasma disposition and adverse effects of voriconazole administered orally in immunocompromised patients.
Yamada T; Mino Y; Naito T; Kawakami J
J Infect Chemother; 2019 Dec; 25(12):1019-1025. PubMed ID: 31239195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
